T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies

(2016) Roy Fleischmann et al.   International Journal of Rheumatic Diseases

The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- B positive feedback loop in peripheral T-cell lymphoma

(2015) R. L. Boddicker et al.   BLOOD

Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

(2015) Ramona Crescenzo et al.   CANCER CELL

Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma

(2015) S. Jain et al.   CLINICAL CANCER RESEARCH

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project

(2015) Youn H. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

(2015) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108

(2015) Paul M. Barr et al.   JOURNAL OF CLINICAL ONCOLOGY

Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells

(2015) Can Küçük et al.   Nature Communications

ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes

(2014) E. R. Parrilla Castellar et al.   BLOOD

GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features

(2014) T. Wang et al.   BLOOD

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

(2014) S. M. Horwitz et al.   BLOOD

Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

(2014) J. Iqbal et al.   BLOOD

Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry

(2014) F. Ellin et al.   BLOOD

Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma

(2014) Ethan Toumishey et al.   CANCER

Therapeutic options in relapsed or refractory peripheral T-cell lymphoma

(2014) Bertrand Coiffier et al.   CANCER TREATMENT REVIEWS

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

(2014) Michinori Ogura et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis

(2014) J H Schatz et al.   LEUKEMIA

Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas

(2014) Teresa Palomero et al.   NATURE GENETICS

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma

(2013) O. Odejide et al.   BLOOD

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial

(2013) Franck Morschhauser et al.   EUROPEAN JOURNAL OF CANCER

Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma

(2013) Sonali M. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors

(2013) Vivien Mak et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

(2013) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)

(2013) Kristen Ganjoo et al.   LEUKEMIA & LYMPHOMA

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas

(2012) G. Vasmatzis et al.   BLOOD

Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters

(2012) F. Lemonnier et al.   BLOOD

IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma

(2012) R. A. Cairns et al.   BLOOD

Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma

(2012) Daruka Mahadevan et al.   CANCER

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

(2012) Barbara Pro et al.   JOURNAL OF CLINICAL ONCOLOGY

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

(2012) Francesco d'Amore et al.   JOURNAL OF CLINICAL ONCOLOGY

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

(2012) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY

JAK/STAT signaling in hematological malignancies

(2012) W Vainchenker et al.   ONCOGENE

Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma

(2012) Ghee Chong Koo et al.   Cancer Discovery

Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing

(2010) A. L. Feldman et al.   BLOOD

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

(2010) N. Schmitz et al.   BLOOD

Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95

(2010) Audrey Simon et al.   BRITISH JOURNAL OF HAEMATOLOGY

The ITK-SYK Fusion Oncogene Induces a T-Cell Lymphoproliferative Disease in Mice Mimicking Human Disease

(2010) C. Dierks et al.   CANCER RESEARCH

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY

Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study

(2008) Peter Reimer et al.   JOURNAL OF CLINICAL ONCOLOGY